project year

2025

A new targeted therapy for resistant HER2+ breast cancers

A targeted therapy to enhance treatment efficacy and neuroprotection in glioblastoma

Advanced pre-clinical evaluation of sphingosine kinase 1-targeting agents as a therapy for acute myeloid leukaemia

Advancing CAR-T cell therapy for extracranial solid paediatric cancers

Advancing Liquid Biopsy Testing: Harnessing Epigenetics for Early Detection of Residual and Recurrent Breast Cancer

Advancing Telomerase Inhibitors as potential cancer therapeutics

Creating the Next Generation in Radiotherapy Imaging with Carbon Nanotube Sources and Photon Counting Detectors

Defining the circulating genome of high-risk plasma cell disorders to improve risk stratification and clinical management

Doubling access while halving toxicity with adaptive lung cancer radiotherapy

Dual targeting of oncogenic cofactors MYC and histone deacetylase in high-risk childhood brain tumours

Engineering childhood cancer for precision medicine

Exploiting a new epigenetic regulatory mechanism for sustaining leukaemia-initiating activity

Improved MRI-guided radiotherapy for pancreatic cancer enabled by robust artificial intelligence

Improving our understanding of the oncogenic signalling-metabolism nexus to design better treatments for pancreatic cancer

Leveraging stem-like memory T cells for effective anti-cancer mRNA vaccines

MARCH5 is a master regulator of BCL2 proteins and a potential anti-cancer drug target

Nanobody-mediated modulation of unconventional T cells for cancer immunotherapy

Pan-cancer assessment of sensitivity towards novel selective oncogenic JNK inhibitors

Precision targeting of regulatory T cells for solid cancer immunotherapy

Predicting clinical response to breast cancer therapy – the immune signature approach

Priming with Belinostat to chemo-sensitise high-risk neuroblastoma

Protein Biosignatures for Predicting Recurrence of Stage II Colorectal Cancer

Resolving prostate cancer: Elucidating the epigenetics of tumour microenvironment cells to advance understanding of disease aetiology and improve patient diagnosis

Selective manipulation of tumour-stroma signalling as a novel precision medicine approach: targeting treatment resistance in pancreatic cancer

Selective targeting of CDK4 to improve breast and prostate cancer treatment

Targeting aggressive cancers that use the Alternative Lengthening of Telomeres (ALT) mechanism

Targeting pancreatic cancer (PC) via anti-fibrotic NID2 therapy and Gemcitabine/Abraxane chemotherapy treatment: stratifying PC therapy

Uncovering the biology of Chronic Myelomonocytic Leukaemia to identify prognostic and treatment opportunities

Unveiling the potential of copper chelation as a cutting-edge epigenetic therapy for Diffuse Midline Glioma

Help us to put an end to cancer